Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”
Journal of Nuclear Medicine · 29.10.2026 · jnumed.126.274063
DOI: 10.2967/jnumed.126.274063 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 29.10.2026. Verfasst von Jeremie Calais und 1 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
REPLY: We thank Dr. Çınar for the interest in our RE-LuPSMA protocol ([1][1]) and for raising the question of biologic heterogeneity at the time of rechallenge. First, a clarification on eligibility. RE-LuPSMA enrolls patients who responded to a prior course of [177Lu]Lu-PSMA-617 and progressed
Zitieren
APA
Calais, J., & RE-LuPSMA investigators (2026). Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”. Journal of Nuclear Medicine, jnumed.126.274063. https://doi.org/10.2967/jnumed.126.274063
Vancouver
Calais J, RE-LuPSMA investigators. Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”. Journal of Nuclear Medicine. 2026:jnumed.126.274063. doi:10.2967/jnumed.126.274063
BibTeX
@article{Calais2026,
author = {Calais, Jeremie and RE-LuPSMA investigators, RE-LuPSMA investigators},
title = {Reply to “Beyond Prostate-Specific Antigen Response: Could 18 F-FDG PET Refine Patient Selection for Rechallenge with [ 177 Lu]Lu-PSMA-617?”},
journal = {Journal of Nuclear Medicine},
year = {2026},
pages = {jnumed.126.274063},
doi = {10.2967/jnumed.126.274063}
}
EUVIMED